Mechanistic comparison of Medroxyprogesterone Acetate and Megestrol Acetate Megestrol acetate is based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
21
Shared Targets
51%
Jaccard Similarity
42%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
Medroxyprogesterone and Megestrol share 21 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.512 means 51% of the combined target set is bound by both compounds. The IDF-weighted score of 0.424 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Medroxyprogesterone and Megestrol have in common?
Medroxyprogesterone and Megestrol share 21 molecular targets with a Jaccard similarity of 51%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Medroxyprogesterone and Megestrol be combined?
Medroxyprogesterone and Megestrol share 21 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Medroxyprogesterone or Megestrol?
In the BiohacksAI corpus: Medroxyprogesterone has 299 PubMed-indexed studies, Megestrol has 300 studies.